Supplementary Fig. S5 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Jiang Chen; Zohreh Amoozgar; Xin Liu; Shuichi Aoki; Zelong Liu; Sarah M. Shin; Aya Matsui; Alexei Hernandez; Zhangya Pu; Stefan Halvorsen; Pin‐Ji Lei; Meenal Datta; Lingling Zhu; Zhiping Ruan; Lei Shi; Daniel Staiculescu; Koetsu Inoue; Lance L. Munn; Dai Fukumura; Peigen Huang; Slim Sassi; Nabeel Bardeesy; Won Jin Ho; Rakesh K. Jain; Dan G. Duda

doi:10.1158/2326-6066.25523606.v1

Abstract

Supplementary Fig. S5: CTLA-4 blockade is critical for efficacy of combined chemotherapy with ICB in ICC by grafting 425 murine cells in C57Bl/6/FVB F1 mice.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2024) studied this question.

synapsesocial.com/papers/68e70c5ab6db643587686041 https://doi.org/10.1158/2326-6066.25523606.v1

View Full Paper

Ask AI

Bookmark

Share

Supplementary Fig. S5 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Abstract

Discussion

Cite This Study

Supplementary Fig. S5 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Abstract

Discussion

Cite This Study

Keep reading

Keep reading